Evolva’s revenues up 25%, shifting product focuses to stevia, nootkatone, and resveratrol

In Switzerland, Evolva announced positive 2015 financial results, with revenues up 25% to CHF 13.4 million and manufacturing efficiency for launched products improving by c. 50% in the last 18 months. The company intends to focus on three highly profitable products in the near term: stevia, nootkatone, and resveratrol. After its launch of both its nootkatone product in 2015, the company is seeking expanded collaboration with the CDC on its nootaktone product, with a focus on mosquitoes that transmit the Zika virus. On the flip side, the launch of the company’s EverSweet stevia product has been delayed beyond 2016.

The company also highlighted its two new partnerships formed in 2015 with Takasago and Valent.

More on the story.